Ventricular Tachycardia (RADIATE-VT Trial)

Hartford HealthCare is proud to share its selection as 1 of 10 initial U.S. sites for the pivotal RADIATE-VTTM clinical trial, sponsored by Varian, a Siemens Healthineers company. The RADIATE-VT trial (NCT 05765175) is the first international, multi-center, randomized controlled trial to evaluate the safety and efficacy cardiac radioablation (CRA) with Varian's CRA system compared to repeat catheter ablation for patients with high-risk refractory ventricular tachycardia (VT).

Varian announced receipt of its Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) for the trial in early January. In 2021, their CRA system received FDA Breakthrough Device designation.

Hartford HealthCare is now enrolling for this study at Hartford Hospital, making us the first in Connecticut and the only hospital in the region to offer such treatment for refractory VT.

Varian's CRA system provides non-invasive delivery of precisely targeted high-dose radiation, enabling ablation across the full thickness of the myocardium, with the potential for fewer side effects while achieving comparable control of a patient's VT relative to current cardiac ablation techniques.

Criteria: To be eligible for the trial, among other inclusion criteria patients must:

  • Have failed catheter ablation and amiodarone for VT treatment (or be intolerant to amiodarone)
  • Be a candidate for a second VT ablation, or cardiac radioablation
  • Not be on hemodynamic support or mechanical ventilation
  • Have an implanted cardioverter defibrillator (ICD)

Location(s): Hartford Hospital
Contact(s): Megan Scalzo, 860.972.4268
Sponsor(s): Varian